Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | GYS1 | P13807 | 3/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2012370 | 0.86 | GYS1 (0.52) | MAOBGYS1GSTP1 | |
| SCHEMBL2030541 | 0.84 | MAOB (0.44) | MAOBF10GRM5FFAR1MAOA | |
| SCHEMBL2009537 | 0.83 | MAOB (0.46) | MAOBF10GRM5FFAR1 | |
| SCHEMBL2011729 | 0.81 | GYS1 (0.54) | MAOBGYS1 | |
| SCHEMBL2012405 | 0.81 | GYS1 (0.54) | MAOBGYS1GSTP1 | |
| SCHEMBL1756377 | 0.80 | MRGPRX4 (0.65) | NR4A2 | |
| SCHEMBL1767152 | 0.79 | MAOB (0.56) | MAOBFFAR1MAOA | |
| SCHEMBL2010257 | 0.79 | GYS1 (0.68) | GYS1 | |
| SCHEMBL4159809 | 0.78 | CNR1 (0.42) | — | |
| SCHEMBL1756359 | 0.77 | MRGPRX4 (0.67) | MAOBNR4A2GYS1F10PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011067266-A1 | CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | MAOB 1010/4885NR4A2 2034/4885GYS1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.